Volume 86 Issue 32 | p. 21 | Concentrates
Issue Date: August 11, 2008

ImClone Rebuffs Buyout Bid From Bristol-Myers Squibb

Department: Business

ImClone Systems says its board of directors and outside advisers are reviewing Bristol-Myers Squibb's $4.5 billion bid to acquire the 83% of the biopharmaceutical company it doesn't already own. The board's initial view, however, is that the $60-per-share offer "substantially undervalues" the firm. ImClone's stock price jumped from about $45 per share before the offer to about $64 per share now. ImClone Chairman Carl C. Icahn, who owns 14% of the company, says . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society